DHR 다나허 코퍼레이션 · Danaher Corporation

뚜렷한 변화 없음 · 1개월 +6.0% · PER 37배.

종가$233.86
시가총액$1,610억
업종헬스케어
다음 실적 발표2026-10-21
PER37.2배
매출 성장(최근 4분기)+5.5%
영업이익률20%
애널리스트 순상향률+12%
목표가 상승여력+5.7%
공매도 거래 비중41%
유명 투자자 보유4곳
1년 수익률+13%

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technolog

2026-10-21 기준 · 출처: SEC EDGAR, FINRA, yfinance · 정보 제공용이며 투자 권유가 아닙니다

같은 업종 종목